Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.1452W HIGH $34.60
Volume
597.47 K
Value Traded
312.29 K
Short % Float
1.89%
Days to Cover
1.0
-24.65%Week
-48.68%1 Month
-92.43%3 Month
-97.62%6 Month
-99.96%5 Year
-99.96%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.06 M
EPS (TTM)
-0.96
P/E Ratio
-
Ent. Value
-169.45 K
Total Shares
14.47 M
Float Shares
8.59 M
Insiders
40.68%
Institutions
0.14%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
SLXN Catalyst Timeline
Dated clinical, regulatory and corporate events for Silexion Therapeutics Corp
Catalyst Timeline
Dated clinical, regulatory & corporate events for Silexion Therapeutics Corp
143Total events
7Upcoming
13Tier-1 (high impact)
2023 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲First Patient DosedSIL-204FiledTrial
First patient dosed in Phase 2/3 trial of SIL204 in LAPC
locally advanced pancreatic cancersource ↗
▼Equity OfferingCorporate
Definitive agreements for immediate exercise of Series E warrants for gross proceeds of ~$837,366
▲Preclinical PoCSIL-204FiledPreclinical
SIL204 harnesses native serum lipoproteins for cellular uptake and dose-dependent mutant KRAS knockdown
KRAS-driven cancerssource ↗
●R&D DayPresentation
Silexion participation in H.C. Wainwright 28th Annual Global Investment Conference
●R&D DayPresentation
Silexion presentation at 8th Annual RAS-Targeted Drug Development Summit
●R&D DayPresentation
Silexion presentation at Oncology & Immunology Innovation Partnering & Licensing Summit
▼Equity OfferingCorporate
Closed registered public offering with gross proceeds of approximately $2.5 million
▲Preclinical PoCSIL-204FiledPreclinical
SIL204 demonstrates immune sensitization via FAS upregulation and HLA-G downregulation in KRAS-mutant cell lines
KRAS-driven cancerssource ↗
◆Enrollment UpdateSIL-204FiledTrial
Patient screening expected to commence at TASMC in coming weeks
locally advanced pancreatic cancersource ↗
▲Preclinical PoCSIL-204FiledPreclinical
Reported additional upregulation of FAS and downregulation of HLA-G across three KRAS mutations
KRAS-mutant pancreatic and non-small cell lung cancersource ↗
▲Trial InitiationSIL-204FiledTrial
Initiated Phase 2/3 clinical trial at Tel Aviv Sourasky Medical Center
locally advanced pancreatic cancersource ↗
◆First Patient DosedSIL-204FiledTrial
First patient dosing expected in coming weeks
locally advanced pancreatic cancersource ↗
▲Trial InitiationSIL-204FiledTrial
Initiation of first clinical trial site at Tel Aviv Sourasky Medical Center
locally advanced pancreatic cancersource ↗
▲IND ClearanceSIL-204FiledIND
BfArM approval to initiate Phase 2/3 trial of SIL204 in Germany
locally advanced pancreatic cancersource ↗
▲Other Regulator MilestoneSIL-204FiledEx-US Regulatory
BfArM authorization in Germany received
locally advanced pancreatic cancersource ↗
▲FDA Filing AcceptedSIL-204FiledRegulatory Filing
Received CTA approval from BfArM
locally advanced pancreatic cancersource ↗
▲Preclinical PoCSIL-204FiledPreclinical
Positive preclinical findings: SIL204 increases MHC-I expression in KRAS G12R-mutated pancreatic cancer cells
KRAS-driven pancreatic cancersource ↗
▲Manufacturing MilestoneSIL-204FiledCMC / Inspection
Initiation of GMP clinical batch manufacturing of SIL204 with Catalent
locally advanced pancreatic cancersource ↗
▲Trial InitiationSIL-204FiledTrial
Helsinki Ethics Committee of Tel Aviv Sourasky Medical Center approved planned Phase 2/3 trial
locally advanced pancreatic cancersource ↗
▼Equity OfferingCorporate
May 2026 warrant exercise inducement transaction generating ~$1.0M gross proceeds
▼Reverse Stock SplitCorporate
Shareholder approval obtained for prospective reverse share split
●Manufacturing MilestoneSIL-204FiledCMC / Inspection
Initiated GMP clinical supply manufacturing with CDMO
locally advanced pancreatic cancersource ↗
▲Other Regulator MilestoneSIL-204FiledEx-US Regulatory
TASMC institutional ethics approval for Phase 2/3 trial
locally advanced pancreatic cancersource ↗
▲Preclinical PoCSIL-204FiledPreclinical
Reported statistically significant upregulation of MHC-I following SIL204 treatment
KRAS-mutant pancreatic and non-small cell lung cancersource ↗
▲IND SubmissionSIL-204FiledIND
Successful submission of Phase 2/3 CTA to Germany's BfArM for SIL204
locally advanced pancreatic cancersource ↗
▲IND ClearanceSIL-204FiledIND
Approval from Israeli Ministry of Health to initiate Phase 2/3 trial
locally advanced pancreatic cancersource ↗
●NDA SubmissionSIL-204FiledRegulatory Filing
Clinical Trial Application submitted to Germany via EU CTIS
locally advanced pancreatic cancersource ↗
●Trial InitiationSIL-204FiledTrial
Phase 2/3 clinical trial initiation planned for Q2 2026
locally advanced pancreatic cancersource ↗
●IND SubmissionSIL-204FiledIND
Submitted Clinical Trial Application to BfArM
locally advanced pancreatic cancersource ↗
▲Other Regulator MilestoneSIL-204FiledEx-US Regulatory
Israeli Ministry of Health authorization received
locally advanced pancreatic cancersource ↗
▲IND ClearanceSIL-204FiledIND
Israeli Ministry of Health approval to initiate Phase 2/3 trial of SIL204
locally advanced pancreatic cancersource ↗
◆Equity OfferingCorporate
Extraordinary General Meeting to vote on authorized share capital increase and equity incentive plan amendment
◆Oral PresentationPresentation
Silexion management attends 7th RNAi-Based Therapeutics Summit
◆Timing GuidanceSIL-204FiledPresentation
Phase 2/3 clinical trial application submission in Germany planned
locally advanced pancreatic cancersource ↗
●IND SubmissionSIL-204FiledIND
Regulatory submission in Germany expected during Q1 2026
locally advanced pancreatic cancersource ↗
◆Other Regulator MilestoneSIL-204FiledEx-US Regulatory
Planned regulatory filings in Germany and EU for SIL204
locally advanced pancreatic cancersource ↗
●EU MAA SubmissionSIL-204FiledEx-US Regulatory
Regulatory submission to European Union expected in Q1 2026
KRAS-driven cancerssource ↗
◆IND ClearanceSIL-204FiledIND
Anticipate response from Israeli regulator on Phase 2/3 trial initiation
locally advanced pancreatic cancersource ↗
◆Trial InitiationSIL-204FiledTrial
Initiation of human clinical trials for SIL204
KRAS-driven cancerssource ↗
▲Other Regulator MilestoneSIL-204FiledEx-US Regulatory
Submission of Phase 2/3 clinical trial application to Israel for SIL204
locally advanced pancreatic cancersource ↗
▲FDA Feedback ReceivedSIL-204FiledFDA Meeting
Positive Scientific Advice response from German BfArM for SIL204
locally advanced pancreatic cancersource ↗
Past FDA Catalysts and PDUFA Decisions
How SLXN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-02-03 | siG12D-LODER (Loder) | Phase 2 data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 100%
Micro Cap(rank 657 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every SLXN program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Shirvan MitchellOfficer (CSO and CDO) | Sell | -22,818 27,889 held | $1.36 | 03/26/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SLXN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in SLXN for Q2 2026. | ||||
SLXN Institutional Ownership Trends
SLXN Short Interest
Shares sold short, counted twice a month.
1.89%
Short % of Float
of tradable shares sold short
162.7K
Shares Sold Short
-96.7% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
1.6M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How SLXN ranks across every disease it competes in
Competitive Position is a premium feature
See how SLXN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSLXN News
SLXN▼ -12.9%on this news
Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
Silexion Therapeutics has announced the successful dosing of the first patient in its Phase 2/3 clinical trial for SIL204, targeting locally advanced pancreatic cancer. The trial will evaluate SIL204 in combination with standard chemotherapy, utilizing a novel delivery method. The study aims to enroll approximately 166 patients globally, with preliminary results anticipated soon.
Read more →SLXN▲ +28.2%on this newsshared move
Silexion Therapeutics Announces Exercise of Warrants
Silexion Therapeutics Corp. has announced the immediate exercise of series E warrants, generating approximately $837,366 in gross proceeds. The company plans to use the funds for general corporate purposes. Additionally, new unregistered Series F and G warrants will be issued with an exercise price of $0.2603 per share. The offering is expected to close on September 29, 2026, pending customary conditions.
Read more →SLXNSilexion Therapeutics Reports Positive Preclinical Findings for SIL204, Demonstrating Key Mechanism for Endogenous Systemic Uptake in KRAS-Driven Cancers
Silexion Therapeutics has reported encouraging preclinical findings for SIL204, its lead candidate targeting KRAS-driven cancers. The study confirms that SIL204 can utilize native serum lipids for effective cellular uptake and gene silencing without the need for artificial carriers. This mechanism supports the drug's potential for systemic administration in ongoing Phase 2/3 clinical trials.
Read more →SLXNSilexion Therapeutics to Participate in September 2026 Industry and Investor Conferences
Silexion Therapeutics Corp. is set to participate in several industry and investor conferences in September 2026, showcasing its advancements in RNA interference therapies for KRAS-driven cancers. The company will present its investigational therapy, SIL204, at key events, highlighting its ongoing Phase 2/3 clinical program for locally advanced pancreatic cancer. Management will be available for meetings to discuss their innovative approaches and future plans.
Read more →SLXN▼ -8.7%on this news
Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Silexion Therapeutics has transitioned its product SIL204 into an active Phase 2/3 clinical trial for locally advanced pancreatic cancer, following regulatory approvals in Israel and Germany. The company reported significant progress in its operational and financial readiness, alongside promising preclinical data supporting its immuno-oncology profile. However, it also noted an increase in net loss and R&D expenses during the second quarter of 2026.
Read more →SLXN▼ -56.1%on this newsshared move
Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering
Silexion Therapeutics has announced the pricing of a public offering, raising approximately $2.5 million by offering 3,846,161 ordinary shares and series E warrants. The proceeds will be used to advance the SIL204 clinical trial and for general corporate purposes. The offering is expected to close around August 13, 2026, pending customary conditions.
Read more →SLXNSilexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers
Silexion Therapeutics announced positive preclinical findings for SIL204, showing its ability to enhance immune response in KRAS-driven cancers. The treatment significantly upregulated FAS and downregulated HLA-G in various KRAS-mutant cell lines. These results support the rationale for combining SIL204 with anti-PD-(L)1 therapies as the company advances into Phase 2/3 clinical trials.
Read more →SLXN▼ -34.7%on this news
Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Center
Silexion Therapeutics has successfully initiated a Phase 2/3 clinical trial for SIL204 at Tel Aviv Sourasky Medical Center, marking a significant milestone in the program's transition to active clinical execution. The trial aims to evaluate SIL204 in combination with standard chemotherapy for locally advanced pancreatic cancer. Patient screening is expected to commence soon, with additional trial sites in Israel and Germany anticipated to join the program.
Read more →SLXNSilexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
Silexion Therapeutics has received approval from Germany's BfArM to start a Phase 2/3 clinical trial of SIL204 for locally advanced pancreatic cancer. This approval follows a similar authorization in Israel, allowing the company to proceed with patient dosing in both countries. The trial aims to evaluate SIL204 in combination with standard chemotherapy, targeting a significant unmet need in oncology.
Read more →SLXN▲ +7%on this newsshared move
Silexion Therapeutics to Attend BIO International Convention 2026
Silexion Therapeutics Corp. will attend the 2026 BIO International Convention in San Diego, CA, from June 22-25. The company's management, including CEO Ilan Hadar and CFO Mirit Horenshtein-Hadar, will hold one-on-one meetings during the event. Silexion focuses on RNA interference therapies for KRAS-driven cancers and is advancing its lead product candidate, SIL204.
Read more →SLXN▼ -14.1%on this news
Silexion Therapeutics Announces 1-for-10 Reverse Share Split
Silexion Therapeutics announced a 1-for-10 reverse share split, effective after market close on May 28, 2026, to promote compliance with Nasdaq's minimum bid price requirement. This move is aimed at reinforcing the company's capital structure ahead of a planned Phase 2/3 trial for SIL204 in pancreatic cancer. The reverse split is expected to reduce share volatility and broaden the investor base. Shareholders will see adjustments made automatically with no action needed on their part.
Read more →SLXN▼ -5.4%on this news· ran to +64% by day 3
Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Silexion Therapeutics announced the approval of its Phase 2/3 clinical trial of SIL204 by the Israeli Ministry of Health, marking a pivotal advancement for the company. The Clinical Trial Application has been successfully submitted to Germany, with trial initiation expected in Q2 2026. Financial results revealed a substantial net loss and decreased cash reserves, highlighting the need for ongoing capital support. Silexion is focused on developing innovative RNA interference therapies for KRAS-driven cancers, particularly pancreatic cancer.
Read more →SLXN▼ -42.1%on this newsshared move
Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds
Silexion Therapeutics Corp. has announced the exercise of outstanding warrants, which is expected to yield approximately $1 million in gross proceeds. The proceeds will be utilized for general corporate purposes. The company continues to advance its oncology-focused pipeline, particularly its lead product candidate SIL204, which targets KRAS-driven cancers. The offering is anticipated to close on May 18, 2026, pending customary closing conditions.
Read more →SLXN▼ -9.3%on this news· ran to -51% by day 3shared move
Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic Cancer
Silexion Therapeutics has reported promising preclinical findings for its candidate SIL204 in treating KRAS-driven pancreatic cancer. The study indicated a significant increase in the expression of MHC-I in human pancreatic cancer cells with the KRAS G12R mutation. This suggests that SIL204 could enhance the effectiveness of immunotherapy by improving immune system recognition of tumor cells. The company continues to advance its clinical trials, positioning SIL204 as a potential breakthrough in the treatment of this challenging cancer type.
Read more →SLXN▼ -5%on this news· ran to -53% by day 3shared move
Silexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Center
Silexion Therapeutics has initiated GMP clinical supply manufacturing of SIL204, a next-generation siRNA therapy targeting KRAS mutations, in collaboration with Catalent. The Helsinki Ethics Committee has approved a Phase 2/3 trial for SIL204 at Tel Aviv Sourasky Medical Center, marking a significant milestone in the company's clinical development. This progress reflects Silexion's commitment to advancing treatment for locally advanced pancreatic cancer.
Read more →SLXN▼ -12.8%on this news
Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany’s BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic Cancer
Silexion Therapeutics has successfully submitted a Clinical Trial Application for its Phase 2/3 trial of SIL204 in KRAS-driven locally advanced pancreatic cancer to Germany's BfArM. This marks a significant regulatory milestone and follows positive feedback from German authorities. The trial aims to evaluate SIL204 alongside standard chemotherapy, with plans to initiate in the second quarter of 2026.
Read more →SLXN▲ +17.5%on this news
Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
Silexion Therapeutics has received approval from the Israeli Ministry of Health to start a Phase 2/3 clinical trial for SIL204, aimed at treating locally advanced pancreatic cancer. This approval follows promising preclinical results and successful toxicology studies. The company plans to initiate the trial in Q2 2026 and expand development to other KRAS-driven cancers.
Read more →SLXNSilexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Silexion Therapeutics has reported its financial results for Q4 and full year 2025, highlighting substantial preclinical progress for its candidate SIL204 against various KRAS mutations. The company achieved clinical readiness milestones, including toxicology studies and regulatory submissions for upcoming trials. Financially, Silexion raised over $18.6 million during the year and regained compliance with Nasdaq listing rules. A Phase 2/3 clinical trial is planned to begin in mid-2026, targeting locally advanced pancreatic cancer.
Read more →SLXNSilexion Therapeutics Urges Shareholders to Vote Ahead of March 16 Extraordinary General Meeting
Silexion Therapeutics Corp. has called for its shareholders to participate in the upcoming Extraordinary General Meeting (EGM) set for March 16, 2026. The proposals on the agenda include a significant increase in the authorized share capital and an amendment to the equity incentive plan aimed at strengthening employee and director retention. The Board encourages shareholders to vote in favor of all proposals as they align with the company's strategy to support its lead product candidate, SIL-204, and pursue future growth opportunities.
Read more →SLXN▼ -5.8%on this news
Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit
Silexion Therapeutics Corp. announced participation in the 7th RNAi-Based Therapeutics Summit scheduled for January 27-29 in Boston, MA. CEO Ilan Hadar and other management will attend to engage in one-on-one meetings with stakeholders. The company is progressing its SIL204 therapy, targeting mutated KRAS oncogenes, into a Phase 2/3 clinical trial for locally advanced pancreatic cancer planned for mid-2026. Silexion is recognized as an official partner of the summit, indicating its active role in the development of RNA-based treatments for various diseases.
Read more →About Silexion Therapeutics Corp
Headquarters12 ABBA HILLEL ROAD, RAMAT GAN, L3, 5250606
BIOPHARMAWATCH ELITE PLUS
Trade the next SLXN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime